Introduction
Anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are specific indicators of patients with dermatomyositis, particularly clinically amyopathic dermatomyositis (CADM) [1e6] . CADM is occasionally accompanied by fatal, treatment-resistant, rapidly-progressive interstitial lung disease (RP-ILD) [7, 8] . A few reports have shown that diffuse alveolar damage (DAD) is a histopathological finding in RP-ILD with anti-MDA5 antibody-positive CADM. However, these findings were confirmed only at autopsy [9, 10] . To our knowledge, this is the first case report to show a non-DAD pattern in RP-ILD with anti-MDA5 antibody-positive CADM, which was improved by immunosuppressive therapy.
Case report
A 32-year-old woman was referred to our hospital with a 4-week history of fever, cough, and erythematous eruptions. She was a never-smoker and had no significant medical history or environmental risk for respiratory disease. Her physical examination revealed a fever (38.3 C), facial erythema and heliotrope rash (Fig. 1a) , erythema over the V area of the neck (Fig. 1b) , scaly erythema with ulceration over the elbow (Fig. 1c) , knee, and dorsum of her hands (Gottron's sign) (Fig. 1d) , and skin thickening on the sides of her fingers (mechanic hands). There were no signs of muscle weakness. Fine crackles were heard in the bilateral lower lung fields. Arterial blood gas analysis showed normal partial pressure of oxygen and carbon dioxide (73.5 and 38.6 Torr, respectively). The alveolar-arterial oxygen difference was 28 mmHg. The serum levels of C-reactive protein and creatine kinase were not elevated. The serum levels of Krebs von den Lungen-6, lactate dehydrogenase, Abbreviations: MDA5, melanoma differentiation-associated gene 5; CADM, clinically amyopathic dermatomyositis; RP-ILD, rapidly progressive interstitial lung disease; DAD, diffuse alveolar damage; CT, computed tomography; FVC, forced vital capacity; DLco, diffusing capacity of the lung for carbon monoxide; 6MWD, six-min walk distance; MMRC, modified medical research council dyspnea scale; NSIP, nonspecific interstitial pneumonia; IVCY, intravenous cyclophosphamide. 
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Respiratory Medicine Case Reports aldolase, and ferritin were increased (726 U/ml, 551 U/l, 10.0 IU/l, and 1269 ng/ml, respectively). Anti-MDA5 antibody was detected (40.7 U/ml > 8 U/ml). Other autoantibodies suggesting autoimmune disorders were not detected. A chest computed tomography (CT) scan showed peribronchovascular ground-glass opacities and bilateral subpleural reticular opacities (Fig. 2) . A pulmonary function test indicated normal predicted value for forced vital capacity (%FVC) and decreased predicted value for diffusing capacity of the lung for carbon monoxide (%DLco) (%FVC 86.5%; %DLco 71.9%). Bronchoalveolar lavage was performed in right B9. The total cell count was 1.38 Â 10 5 cells m
À1
, with a normal cellular profile and CD4/CD8 ratio (the percentage of neutrophils and lymphocytes were 2 and 0%, respectively). Microbial culture results from the sputum and bronchoalveolar lavage fluid were negative. Six-min walk distance (6MWD) was 285 m, with 96% of minimum arterial oxygen saturation measured by pulse oximetry. The modified medical research council dyspnea scale (MMRC) was 2. Magnetic resonance imaging of inferior retinaculum of extensor muscles demonstrated muscle edema that was consistent with myositis. In a muscle biopsy, findings of perivascular inflammatory infiltrate and perifascicular muscle fiber atrophy were obtained. While the definition of CADM by Sontheimer [5] requires that skin disease be present for 6 months without the development of muscle disease, Sontheimer et al. [6] has also described a subset of patients with CADM in whom fatal ILD developed within the first 6 months of their disease course. Although the disease duration was short in our patient, a presumptive diagnosis of CADM with RP-ILD was made on the basis of the described findings. One week after the first visit, in order to determine the histopathological pattern, we performed video-assisted thoracic surgical lung biopsy (SLB) (right S5, 8, 9) .
The lesion was characterized by diffuse mild interstitial fibrosis and inflammatory cell infiltration mostly of lymphocytes, and the changes were homogeneous, as in a nonspecific interstitial pneumonia (NSIP) pattern (Fig. 3a) . Meanwhile, mild peripheral accentuation and inflammatory changes around the respiratory bronchioles were also seen. There were accumulations of foamy macrophages and a few neutrophils in the airspace (Fig. 3b) , and subacute changes such as scant airspace fibrin and scattered Masson bodies as a minor component of the pathology (Fig. 3c, d) . Findings suggestive of DAD such as hyaline membrane, remarkable airspace fibrin, and extensive interstitial edema were not found.
One week after SLB, two cycles of methylprednisolone pulse therapy (1000mg day À1 for 3 days) were initiated, followed by 10 mg of prednisolone and 5 mg of tacrolimus daily. This was associated with a significant resolution of symptoms within 1 month (MMRC was 1). The serum ferritin level decreased to 648 ng/ ml, while %FVC increased to 96.0%. The 6MWD was improved to 560 m. These effects were maintained during the first year of treatment. No adverse events were observed.
Discussion
To our knowledge, this is the first case to show a non-DAD pattern in a survivor with RP-ILD and anti-MDA5 antibody-positive CADM. The important point here is that the histopathological findings indicated non-DAD pattern with a favorable clinical course. All previous reports showed that histopathological findings in RP-ILD with anti-MDA5 antibody-positive CADM indicated DAD [9, 10] . However, our lung biopsy specimens showed diffuse and homogeneous inflammatory cell infiltration similar to NSIP with subacute inflammatory findings, which was different from DAD. These differences may have resulted from the timing of the lung biopsy or a difference in the type of interstitial pneumonia, which influences prognosis. We performed surgical lung biopsy one week after the first visit. Therefore, our lung specimens may reflect the early phase of RP-ILD, which may progress to DAD. Another possibility is that there may be some heterogeneity with regards to ILD pattern in patients with RP-ILD and anti-MDA5 antibody-positive CADM [11] . Further studies are needed to clarify whether or not histopathologic pattern is associated with prognosis in patients with RP-ILD and anti-MDA5 antibody-positive CADM.
In our patient, both onset and histopathological findings were atypical for NSIP. Recent guidelines classified NSIP into chronic fibrosing interstitial pneumonia; however, the present case showed subacute onset [12] . As for histopathological findings, subacute changes were atypical for NSIP. Taken together, we diagnosed the histopathological pattern as unclassifiable interstitial pneumonia.
Another important point in this case is the treatment. Previous studies showed that anti-MDA5 antibody is associated with increased mortality in CADM [1, 2, 4] . Furthermore, some studies showed that high levels of ferritin are associated with the prognosis of anti-MDA5 antibody-positive CADM [2, 13] . For this reason, a combination therapy including intravenous cyclophosphamide (IVCY) is recommended in RP-ILD patients with hyperferritinemia (>500 ng/ml) and/or anti-MDA5 antibody [14] . Although our patient had some poor prognostic factors, improvements were seen in symptoms, pulmonary function, 6MWD, and serum ferritin levels with only corticosteroids and tacrolimus. Wilkes et al. [15] showed that tacrolimus is a well-tolerated and effective therapy for managing refractory ILD and myositis in anti-aminoacyl-transfer RNA synthetase positive patients. Another study showed that combination therapy including IVCY was more frequently received in the dead subset than in the living subset of patients with anti-MDA5 antibody-positive DM [13] . These results suggest that some patients with anti-MDA5 antibody-positive CADM may not need strong immunosuppressive therapy.
In conclusion, this is the first report describing a non-DAD pattern in RP-ILD with anti-MDA5 antibody-positive CADM, which was improved by immunosuppressive therapy. This case may be a milder clinical phenotype than a typical DAD pattern in RP-ILD with anti-MDA5 antibody-positive CADM. Further studies are needed to determine the mechanisms of lung injury and an appropriate treatment of RP-ILD with anti-MDA5 antibody-positive CADM.
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